ACI :: MACI :: OATS :: OC Allograft :: Microfracture :: DeNovo
Clinical Trial :: Treatment of Osteochondritis Dissecans
DeNovo® ET Trial
Dr. David Flanigan is participating in the DeNovo® ET trial. DeNovo® ET is an engineered tissue implant consists of a living cartilage tissue grown in the laboratory, cultured using human cartilage cells.
DeNovo® ET implant is surgically inserted and fixed to the subchondral bone using fibrin glue in patients with cartilage defects.
DeNovo® ET trial is a prospective randomized study to assess the efficacy and safety of the DeNovo® ET tissue implant in treating cartilage defects as compared to microfracture treatment.
The FDA has approved to conduct the phase III clinical trials to demonstrate the efficacy and safety of the DeNovo® ET Implant for the treatment of ICRS Grade 3 to 4 articular cartilage lesions of the knee
compared to microfracture treatment.
For more information on DeNovo ET click here
Neocartilage Implant Phase III Trial
CAIS Clinical Trial
Dr. David Flanigan is participating in the CAIS trial. Cartilage autograft implantation system (CAIS) involves extracting cartilage from the healthy tissue and breaking it into tiny fragments, fixing it onto
a synthetic, resorbable implant using a fibrin sealant, and then implanting into the damaged area in a single surgery through a mini-open knee arthrotomy.
Cartilage autograft implantation system (CAIS) trail is a prospective randomized study to assess the efficacy and safety of the CAIS implant for treating isolated defects of the femur compared to microfracture.
The purpose of conducting phase III clinical trial is to demonstrate the efficacy and safety of the CAIS implant for the treatment of non-OCD lesions (between ICRS grades I and IIID)or OCD lesions (between ICRS
grades I and IVA) of the knee compared to microfracture treatment.
For more information on CAIS trial click here
Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration